Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparid vs Budes Nasal Spray in CRS with Polyposis Nasi
NCT01946711Phase 2Completed
- Sponsor
- PARI Pharma
- Start
- Aug 2013
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of EPI-EE in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by PARI Pharma. Primary endpoint: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus at 8 weeks. Started Aug 2013; status: completed.
02
Drugs
EPI-EE
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT01946711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946711.